WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524955
CAS#: 631-06-1 (HCl)
Description: Dexoxadrol hydrochloride is a dissociative anaesthetic drug which has been found to be an NMDA antagonist.
Hodoodo Cat#: H524955
Name: Dexoxadrol hydrochloride
CAS#: 631-06-1 (HCl)
Chemical Formula: C20H24ClNO2
Exact Mass: 0.00
Molecular Weight: 345.860
Elemental Analysis: C, 69.45; H, 6.99; Cl, 10.25; N, 4.05; O, 9.25
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 4741-41-7 (free base) 631-06-1 (HCl)
Synonym: Dexoxadrol hydrochloride; NSC 526062; NSC-526062; Relane ; U 22558 A; d-Dioxadrol hydrochloride; Dexoxadrol HCl; U-22,559A;UNII-T0C1IR71L8.
IUPAC/Chemical Name: (+)-2-(2,2-Diphenyl-1,3-dioxolan-4-yl)piperidine hydrochloride
InChi Key: GYPWNVSWCIMIHQ-GRTNUQQKSA-N
InChi Code: InChI=1S/C20H23NO2.ClH/c1-3-9-16(10-4-1)20(17-11-5-2-6-12-17)22-15-19(23-20)18-13-7-8-14-21-18;/h1-6,9-12,18-19,21H,7-8,13-15H2;1H/t18-,19+;/m0./s1
SMILES Code: c1ccc(cc1)C2(OC[C@@H](O2)[C@@H]3CCCCN3)c4ccccc4.Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 345.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Utech T, Köhler J, Wünsch B. Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonists. Eur J Med Chem. 2011 Jun;46(6):2157-69. doi: 10.1016/j.ejmech.2011.02.070. Epub 2011 Mar 5. PubMed PMID: 21444132.
2: Banerjee A, Schepmann D, Köhler J, Würthwein EU, Wünsch B. Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonists. Bioorg Med Chem. 2010 Nov 15;18(22):7855-67. doi: 10.1016/j.bmc.2010.09.047. Epub 2010 Sep 25. PubMed PMID: 20965735.
3: Sax M, Ebert K, Schepmann D, Wibbeling B, Wünsch B. Synthesis and NMDA-receptor affinity of 4-oxo-dexoxadrol derivatives. Bioorg Med Chem. 2006 Sep 1;14(17):5955-62. Epub 2006 Jun 5. PubMed PMID: 16750371.
4: Sax M, Wünsch B. Relationships between the structure of dexoxadrol and etoxadrol analogues and their NMDA receptor affinity. Curr Top Med Chem. 2006;6(7):723-32. Review. PubMed PMID: 16719812.
5: Aepkers M, Wünsch B. Structure-affinity relationship studies of non-competitive NMDA receptor antagonists derived from dexoxadrol and etoxadrol. Bioorg Med Chem. 2005 Dec 15;13(24):6836-49. Epub 2005 Sep 19. PubMed PMID: 16169732.
6: Sun W, Wessinger WD. Characterization of the non-competitive antagonist binding site of the NMDA receptor in dark Agouti rats. Life Sci. 2004 Aug 6;75(12):1405-15. PubMed PMID: 15240177.
7: Aepkers M, Wünsch B. Synthesis and NMDA-receptor affinity of ring and side chain homologous dexoxadrol derivatives. Arch Pharm (Weinheim). 2004 Feb;337(2):67-75. PubMed PMID: 14981662.
8: Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC. Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode. J Mol Model. 2002 Feb;8(2):65-72. PubMed PMID: 12032600.
9: Mele A, Wozniak KM, Hall FS, Pert A. The role of striatal dopaminergic mechanisms in rotational behavior induced by phencyclidine and phencyclidine-like drugs. Psychopharmacology (Berl). 1998 Jan;135(2):107-18. PubMed PMID: 9497015.
10: Grant KA, Colombo G, Grant J, Rogawski MA. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology. 1996;35(12):1709-19. PubMed PMID: 9076750.
11: Pechnick RN, Poland RE. Neuroendocrine responses produced by enantiomeric pairs of drugs that interact with phencyclidine and sigma receptors. Eur J Pharmacol. 1994 Sep 22;263(1-2):115-20. PubMed PMID: 7821343.
12: Beardsley PM, Anthony EW, Lopez OT. Phencyclidine established as a discriminative stimulus using ethanol as a reinforcer. Behav Pharmacol. 1992 Oct;3(5):497-505. PubMed PMID: 11224152.
13: Jamieson GA, Agrawal AK, Greco NJ, Tenner TE Jr, Jones GD, Rice KC, Jacobson AE, White JG, Tandon NN. Phencyclidine binds to blood platelets with high affinity and specifically inhibits their activation by adrenaline. Biochem J. 1992 Jul 1;285 ( Pt 1):35-9. PubMed PMID: 1322125; PubMed Central PMCID: PMC1132740.
14: Thurkauf A, Mattson MV, Richardson S, Mirsadeghi S, Ornstein PL, Harrison EA Jr, Rice KC, Jacobson AE, Monn JA. Analogues of the dioxolanes dexoxadrol and etoxadrol as potential phencyclidine-like agents. Synthesis and structure-activity relationships. J Med Chem. 1992 Apr 17;35(8):1323-9. PubMed PMID: 1349351.
15: Domino EF. Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists. J Psychopharmacol. 1992 Jan;6(3):418-24. doi: 10.1177/026988119200600312. PubMed PMID: 22291389.
16: Haring R, Pellegrini-Giampietro DE, Zukin SR, Zukin RS, Scheideler MA. High efficiency reconstitution of a phencyclidine/MK-801 receptor binding site solubilized from rat forebrain membranes. Mol Pharmacol. 1991 Nov;40(5):666-73. PubMed PMID: 1658603.
17: Wang Y, Lee HK. Electrophysiological interactions between NMDA and phencyclidine/sigma receptor agonists and antagonists in Purkinje neurons in the cerebellum of the rat. Neuropharmacology. 1991 Sep;30(9):985-94. PubMed PMID: 1656310.
18: Akunne HC, Reid AA, Thurkauf A, Jacobson AE, de Costa BR, Rice KC, Heyes MP, Rothman RB. [3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse. 1991 Aug;8(4):289-300. PubMed PMID: 1833849.
19: France CP, Moerschbaecher JM, Woods JH. MK-801 and related compounds in monkeys: discriminative stimulus effects and effects on a conditional discrimination. J Pharmacol Exp Ther. 1991 May;257(2):727-34. Erratum in: J Pharmacol Exp Ther 1991 Dec;259(3):1404. PubMed PMID: 2033515.
20: Butelman ER, France CP, Woods JH. The discriminative stimulus effects of MK-801 in pigeons. Behav Pharmacol. 1991 Apr;2(2):79-86. PubMed PMID: 11224051.
